Lifeward Ltd Q2 revenue up 16% on higher ReWalk Personal exoskeleton sales

Lifeward

14/08/2026 14:26

Overview
Biomedical innovator's Q2 revenue rose 16% yr/yr, driven by higher product sales
Adjusted net loss for Q2 widened yr/yr, mainly due to higher clinical trial expenses
Company launched pilot with Ottobock Care to expand U.S. access to ReWalk exoskeleton

Outlook
Lifeward expects revenue momentum to continue in the second half of 2026
Company says expanding distribution partnerships and commercial infrastructure will support future growth
Lifeward says strengthened healthcare platform and pipeline position it for long-term growth

Result Drivers
PRODUCT SALES MIX - Revenue growth was driven by a 13% increase in ReWalk Personal exoskeleton sales, mainly in Europe, and a 25% rise in AlterG product and service revenue in the U.S.
DISTRIBUTION STRATEGY - Co said continued execution of its capital-efficient distribution strategy and new pilot with Ottobock Care expanded patient access and supported commercial growth
GROSS MARGIN PRESSURE - Gross margin declined to 41% from 44% a year earlier, mainly due to higher tariffs, foreign exchange fluctuations, and a 4% revenue sharing expense from the Oramed transaction

Company press release: ID:nGNX2yxXkR

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$6.62 mln
 
Q2 Adjusted Loss Per Share
 
$1.46
 
Q2 Adjusted Net Loss
 
$4.10 mln
 
Q2 Net Loss
 
$11.52 mln
 
Q2 Gross Margin
 
41.00%
 
Q2 Loss Per Basic Share
 
$4.12
 
Q2 Operating Expenses
 
$6.90 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Reuters Recommended Reads
Aug 13 - Israel's MediWound beats Q2 revenue estimates, reaffirms 2026 guidance
Aug 12 - Israel's IceCure Medical H1 revenue rises on higher system, probe sales
Aug 12 - Israel's BrainsWay Q2 revenue rises 35% to record high on higher shipments, utilization

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)